Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRND | Q07001 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568306 | 0.96 | ALOX15 (0.38) | ALOX15ALOX12BACE1MAPTKDM4E | |
| SCHEMBL10042947 | 0.90 | ALOX15 (0.38) | ALOX15ALOX12BACE1MAPTCHRNA1 | |
| SCHEMBL2570309 | 0.90 | ALOX15 (0.43) | ALOX15ALOX12MAPTCHRNA1CHRNG | |
| SCHEMBL2563436 | 0.89 | ALOX15 (0.40) | ALOX15ALOX12BACE1MAPTKDM4E | |
| SCHEMBL2563485 | 0.87 | ALOX15 (0.46) | ALOX15ALOX12BACE1MAPTKDM4E | |
| SCHEMBL10042943 | 0.85 | GAA (0.39) | ALOX15ALOX12LMNACHRNA1CHRNG | |
| SCHEMBL2570965 | 0.85 | ALOX15 (0.40) | ALOX15ALOX12BACE1MAPTKDM4E | |
| SCHEMBL15906350 | 0.84 | ALOX15 (0.35) | ALOX15ALOX12MAPTKDM4ELMNA | |
| SCHEMBL13673338 | 0.83 | SMN1; SMN2 (0.38) | ALOX15ALOX12BACE1MAPTKDM4E | |
| SCHEMBL13673328 | 0.83 | GAA (0.38) | ALOX15ALOX12LMNACHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794141-B1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS INC (US) | 2011-11-09 | — | — | EP | claimed |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-10-06 | — | — | US | disclosed |
| US-9381186-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8084628-B2 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084628-B2 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-12-24 | — | — | US | disclosed |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-12-24 | — | — | US | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 4170/4885ALOX12 4177/4885BACE1 4595/4885 |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 4170/4885ALOX12 4177/4885BACE1 4595/4885 |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 4170/4885ALOX12 4177/4885BACE1 4595/4885 |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 4170/4885ALOX12 4177/4885BACE1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.